Intervention Review

Donepezil for dementia due to Alzheimer's disease

  1. Jacqueline Birks1,*,
  2. Richard J Harvey2

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 25 JAN 2006

Assessed as up-to-date: 4 APR 2006

DOI: 10.1002/14651858.CD001190.pub2

How to Cite

Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001190. DOI: 10.1002/14651858.CD001190.pub2.

Author Information

  1. 1

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  2. 2

    University of Melbourne, Aged Psychiatric Services, Geelong, Victoria, Australia

*Jacqueline Birks, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, OX2 6UD, UK. jacqueline.birks@csm.ox.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 25 JAN 2006

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Akira Nagakura, Yoshitsugu Shitaka, Junko Yarimizu, Nobuya Matsuoka, Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine, European Journal of Pharmacology, 2013, 703, 1-3, 53

    CrossRef

  2. 2
    Katja Hardenacke, Jens Kuhn, Doris Lenartz, Mohammad Maarouf, Jürgen K. Mai, Christina Bartsch, Hans J. Freund, Volker Sturm, Stimulate or Degenerate: Deep Brain Stimulation of the Nucleus Basalis Meynert in Alzheimer Dementia, World Neurosurgery, 2013, 80, 3-4, S27.e35

    CrossRef

  3. 3
    H. Nashawi, T. Bartl, P. Bartl, L. Novotny, M.A. Oriowo, S.B. Kombian, TH-9 (a theophylline derivative) induces long-lasting enhancement in excitatory synaptic transmission in the rat hippocampus that is occluded by frequency-dependent plasticity in vitro, Neuroscience, 2012, 220, 70

    CrossRef

  4. 4
    Daniel Rodríguez, Francesc Formiga, Isabel Fort, María José Robles, Elena Barranco, Dolors Cubí, Tratamiento farmacológico de la demencia: cuándo, cómo y hasta cuándo. Recomendaciones del Grupo de Trabajo de Demencias de la Sociedad Catalana de Geriatría y Gerontología, Revista Española de Geriatría y Gerontología, 2012, 47, 5, 228

    CrossRef

  5. 5
    Albert Diefenbacher, Ronald Burian, Christian Klesse, Martin Härter, Psychische Erkrankungen, 2012,

    CrossRef

  6. 6
    Dietrich van Calker, Jörg Walden, Psychische Erkrankungen, 2012,

    CrossRef

  7. 7
    Michael Hüll, Hans Förstl, Psychische Erkrankungen, 2012,

    CrossRef

  8. 8
    Sara L. Montgomery, Michael A. Mastrangelo, Diala Habib, Wade C. Narrow, Sara A. Knowlden, Terry W. Wright, William J. Bowers, Ablation of TNF-RI/RII Expression in Alzheimer's Disease Mice Leads to an Unexpected Enhancement of Pathology, The American Journal of Pathology, 2011, 179, 4, 2053

    CrossRef

  9. 9
    Harald Hampel, Gordon Wilcock, Sandrine Andrieu, Paul Aisen, Kaj Blennow, K. Broich, Maria Carrillo, Nick C. Fox, Giovanni B. Frisoni, Maria Isaac, Simon Lovestone, Agneta Nordberg, David Prvulovic, Christina Sampaio, Philip Scheltens, Michael Weiner, Bengt Winblad, Nicola Coley, Bruno Vellas, Biomarkers for Alzheimer's disease therapeutic trials, Progress in Neurobiology, 2011, 95, 4, 579

    CrossRef

  10. 10
    Gary Small, Roger Bullock, Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease, Alzheimer's & Dementia, 2011, 7, 2, 177

    CrossRef

  11. 11
    Chris M. Dodds, Edward T. Bullmore, Richard N. Henson, Soren Christensen, Sam Miller, Marie Smith, Odile Dewit, Phil Lawrence, Pradeep J. Nathan, Effects of donepezil on cognitive performance after sleep deprivation, Human Psychopharmacology: Clinical and Experimental, 2011, 26, 8
  12. 12
    Ricardo F. Allegri, Raúl L. Arizaga, Claudia V. Bavec, Liliana P. Colli, Ignacio Demey, María C. Fernández, Silvina A. Frontera, María L. Garau, Julio J. Jiménez, Ángel Golimstok, Janus Kremer, Edith Labos, Carlos A. Mangone, Juan A. Ollari, Galeno Rojas, Omar Salmini, Jorge A. Ure, Daniel R. Zuin, Enfermedad de Alzheimer. Guía de práctica clínica, Neurología Argentina, 2011, 3, 2, 120

    CrossRef

  13. 13
    Kyoung-Ah Kim, Jong Lae Lim, Chin Kim, Ji-Young Park, Pharmacokinetic Comparison of Orally Disintegrating and Conventional Donepezil Formulations in Healthy Korean Male Subjects: A Single-Dose, Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study, Clinical Therapeutics, 2011, 33, 7, 965

    CrossRef

  14. 14
    Serena Deiana, Bettina Platt, Gernot Riedel, The cholinergic system and spatial learning, Behavioural Brain Research, 2011, 221, 2, 389

    CrossRef

  15. 15
    M. Llanero Luque, J.M. Ruiz Sánchez de León, P. Medrano Izquierdo, C. Fernández García, Tratamiento de la enfermedad de Alzheimer, Medicine - Programa de Formación Médica Continuada Acreditado, 2011, 10, 76, 5138

    CrossRef

  16. 16
    Antoine Pariente, Marion Pinet, Yola Moride, Yvon Merlière, Nicholas Moore, Annie Fourrier-Réglat, Factors associated with persistence of cholinesterase inhibitor treatments in the elderly, Pharmacoepidemiology and Drug Safety, 2010, 19, 7
  17. 17
    María Jesús González Moneo, ¿Son útiles los fármacos para el Alzheimer?, FMC - Formación Médica Continuada en Atención Primaria, 2008, 15, 5, 330

    CrossRef

  18. 18
    Lon S. Schneider, Prevention therapeutics of dementia, Alzheimer's & Dementia, 2008, 4, 1, S122

    CrossRef

  19. 19
    Daniel Strech, Jon Tilburt, Value judgments in the analysis and synthesis of evidence, Journal of Clinical Epidemiology, 2008, 61, 6, 521

    CrossRef

  20. 20
    Krista L. Lanctôt, Nathan Herrmann, Commentary on “Health economics and the value of therapy in Alzheimer’s disease.” Cholinesterase inhibitors in Alzheimer’s disease—Evidence-based or evidence-biased?, Alzheimer's & Dementia, 2007, 3, 3, 177

    CrossRef

  21. 21
    Elias M. Schwam, Susan Abu-Shakra, Megan del Valle, Raymond J. Townsend, Maria C. Carrillo, Howard Fillit, Health economics and the value of therapy in Alzheimer’s disease, Alzheimer's & Dementia, 2007, 3, 3, 143

    CrossRef

  22. 22
    Joël Belmin, Renaud Péquignot, Cécile Konrat, Sylvie Pariel-Madjlessi, Prise en charge de la maladie d'Alzheimer, La Presse Médicale, 2007, 36, 10, 1500

    CrossRef

  23. 23
    Weimin Yang, Ming Liu, Junfang Teng, Zilong Hao, Bo Wu, Taixiang Wu, Guan J Liu, Almitrine-Raubasine combination for dementia, The Cochrane Library,
  24. 24
    Ross Overshott, Salman Karim, Alistair Burns, Cholinesterase inhibitors for delirium, The Cochrane Library,
  25. 25
    Rebecca Wild, Tor ACL Pettit, Alistair Burns, Cholinesterase inhibitors for dementia with Lewy bodies, The Cochrane Library,
  26. 26
    Tom C Russ, Joanne R Morling, Cholinesterase inhibitors for mild cognitive impairment, The Cochrane Library,
  27. 27
    Tom C Russ, Joanne Morling, Cholinesterase inhibitors for mild cognitive impairment, The Cochrane Library,
  28. 28
    Roy Jones, Knut Laake, Anne Rita Øksengård, D-cycloserine for Alzheimer's disease, The Cochrane Library,
  29. 29
    Bart M. Demaerschalk, Bryan K. Woodruff, Richard J. Caselli, Dementia Treatment: Let the Evidence Lead us,
  30. 30
    Monica Mohan, Peter K Carpenter, Cathy Bennett, Donepezil for dementia in people with Down syndrome, The Cochrane Library,
  31. 31
    Jacqueline Birks, Leon Flicker, Donepezil for mild cognitive impairment, The Cochrane Library,
  32. 32
    Bincy P Abraham, Joseph H Sellin, Drug-Induced Diarrhea,
  33. 33
    Jun Li, Hong Mei Wu, Rongle L Zhou, Guan Jian Liu, Bi Rong Dong, Huperzine A for Alzheimer's disease, The Cochrane Library,
  34. 34
    Jirong Yue, Bi Rong Dong, Xiufang Lin, Ming Yang, Hong Mei Wu, Taixiang Wu, Huperzine A for mild cognitive impairment, The Cochrane Library,
  35. 35
    Jirong Yue, Bi Rong Dong, Xiufang Lin, Ming Yang, Hong Mei Wu, Taixiang Wu, Huperzine A for mild cognitive impairment, The Cochrane Library,
  36. 36
    Jacqueline Birks, John Grimley Evans, Vasso Iakovidou, Magda Tsolaki, Rivastigmine for Alzheimer's disease, The Cochrane Library,
  37. 37
    Rob Anderson, Ian Shemilt, The Role of Economic Perspectives and Evidence in Systematic Review,